Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem ...

Bristol-Myers Squibb (NYSE:BMY) announced positive results from the Phase 3 POETYK PsA-1 trial of Sotyktu, showcasing its ...

Under this deal, Philochem will grant RayzeBio exclusive worldwide rights to develop, manufacture, and market OncoACP3, a ...

Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

Goldman Sachs 46th Annual Global Healthcare Conference June 11, 2025 10:00 AM ETCompany ParticipantsAdam Lenkowsky ...

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

U.S.-listed shares of BioNTech jumped more than 15% Monday morning after the German vaccine maker announced a collaboration ...

Bristol Myers Squibb has agreed to pay up to $11.1 billion to partner with Germany's BioNTech and develop the latter's ...

Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as ...

By Michael Erman (Reuters) -Bristol Myers Squibb will pay $1.5 billion upfront to partner with Germany's BioNTech on an ...